Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from Heart OMics in AGEing (HOMAGE) trial
Authors' conclusion
Among HOMAGE trial participants, diabetes was a powerful driver of biomarker and echocardiographic alterations irrespectively of CAD. These alterations were mainly related to the domains of inflammation and diastolic function.
Study context
- Population
- People at risk for heart failure (HF) in the HOMAGE trial of spironolactone; mean age 74 years, 25% women; Diabetes mellitus (DM)-/coronary artery disease (CAD)- excludedof 527 in HOMAGE · DM-/CAD- excluded 32
- Participants
- 495 people
- Comparison
- DM+/CAD- and DM+/CAD+ vs DM-/CAD+
Primary result
As reported in the abstract
baseline
- DM+/CAD-
- β, procollagen type I C-terminal propeptide −6.973 (95% CI −13.778 to −0.167); all p < 0.05
- DM+/CAD+
- β, procollagen type I C-terminal propeptide −9.039 (95% CI −15.174 to −2.903); all p < 0.05
- DM+/CAD-
- β, LV end-diastolic volume −6.323 (95% CI −9.696 to −2.951)
- DM+/CAD+
- β, LV end-diastolic volume −2.503 (95% CI −5.531 to 0.526)
- DM+/CAD-
- β, LV end-systolic volume −2.905 (95% CI −4.817 to −0.992)
- DM+/CAD+
- β, LV end-systolic volume −1.400 (95% CI −3.120 to 0.320)
- DM+/CAD-
- exponential β, galectin-3 1.127 (95% CI 1.050–1.209); all p < 0.05
- DM+/CAD+
- exponential β, galectin-3 1.118 (95% CI 1.048–1.192); all p < 0.05
- DM+/CAD-
- exponential β, GDF-15 1.542 (95% CI 1.360–1.747); all p < 0.05
- DM+/CAD+
- exponential β, GDF-15 1.535 (95% CI 1.370–1.720); all p < 0.05
- DM+/CAD-
- β, E/e' ratio 1.355 (95% CI 0.462–2.248); all p < 0.05
- DM+/CAD+
- β, E/e' ratio 0.879 (95% CI 0.067–1.690); all p < 0.05
Further findings
Effect of spironolactone on echocardiographic variables and biomarkers across DM/CAD phenotypes · follow-up
- Not significantly different across DM/CAD phenotypes
- all p-interaction > 0.05
- More pronounced reduction in GDF-15 in DM+/CAD+ at 1-month visit
- P for interaction = 0.03
Original publication
Echocardiographic and biomarker characteristics in diabetes, coronary artery disease or both: insights from HOMAGE trial. Cardiovasc Diabetol. Published 8 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →